Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30498% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Korsana Biosciences's ebitda for the twelve months ending Dec 31, 2023 was -$12.95M. For fiscal 2023 it was -$12.95M. The highest annual figure on record is -$12.95M in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$12.95M | – |
| FY2022 | Dec 31, 2022 | -$18.48M | – |
| FY2021 | Dec 31, 2021 | -$54.72M | – |
| FY2020 | Dec 31, 2020 | -$78.97M | – |
| FY2019 | Dec 31, 2019 | -$122.34M | – |
| FY2018 | Dec 31, 2018 | -$113.72M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$1.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.29M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.69M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.18M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.93M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$32.25M | – |
| Q1 FY2019 | Mar 31, 2019 | -$36.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$30.44M | – |
| Q3 FY2018 | Sep 30, 2018 | -$28.89M | – |
| Q2 FY2018 | Jun 30, 2018 | -$29.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.93M | – |
See a number that looks wrong?